Onderneming OHR Pharmaceutical Inc Nasdaq
Aandelen
US67778H3093
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 10-01-22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 01-11-21 |
Alan Scrivner
LAW | General Counsel | - | 01-09-21 |
Shannon McCarthy
HRO | Human Resources Officer | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 12-07-19 |
Eric Richman
BRD | Director/Board Member | 63 | 12-07-19 |
Director/Board Member | 79 | 12-07-19 | |
Gerald McDougall
BRD | Director/Board Member | 57 | 11-05-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 3 751 590 | 3 249 699 ( 86,62 %) | 0 | 86,62 % |
Bedrijfsgegevens
NeuBase Therapeutics, Inc.
350 Technology Drive Suite 421
15219, Pittsburgh
+
http://www.neubasetherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,86 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,66 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+28,07% | 12,14 mld. | |
+0,17% | 12,15 mld. | |
-1,24% | 11,99 mld. |